Aldgamycins Q 1 and Q 2, two novel 16-membered macrolides from the rare actinomycete Saccharothrix sp. 16Sb2-4.

Autor: Luo K; Department of Microbial Chemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China., Yang Q; Department of Microbial Chemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China., Liu Y; Department of Microbial Chemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China., Sun C; Department of Microbial Chemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China. chenghangsun@hotmail.com., Liu S; Department of Microbial Chemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China. liushaowei3535@163.com.
Jazyk: angličtina
Zdroj: The Journal of antibiotics [J Antibiot (Tokyo)] 2024 Dec; Vol. 77 (12), pp. 842-846. Date of Electronic Publication: 2024 Sep 25.
DOI: 10.1038/s41429-024-00775-7
Abstrakt: Two novel 16-membered macrolides, named aldgamycin Q 1 (1) and Q 2 (2), were isolated from the culture broth of the rare actinomycete Saccharothrix sp. 16Sb2-4. The structures of 1 and 2 were elucidated as new aldgamycin analogs with a demethylated mycinose residue by spectroscopic analyses and comparison with data of aldgamycin K. Compounds 1 and 2 showed moderate to weak antibacterial activities against Enterococcus faecalis, Bacillus subtilis, Staphylococcus aureus and Acinetobacter baumannii, with MIC values ranging from 16 to 64 μg mL -1 .
Competing Interests: Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.)
Databáze: MEDLINE
Externí odkaz: